French pharmaceutical giant Sanofi has entered into exclusive negotiations with US-based private equity firm Advent International to divest its European generics business Zentiva for €1.9bn.

Following the binding deal, the two companies plan to jointly work to establish a new independent operation.

Zentiva offers a wide range of generic medicines across various therapeutic areas. The business caters to more than 40 million patients throughout 25 European countries.

Advent International European healthcare managing director and co-head Tom Allen, and French division managing director and head Cédric Chateau jointly commented: “We have long been attracted to the generics pharmaceutical sector as it enables more people to access high quality treatments by lowering their cost.

“Following a comprehensive review of strategic options for our generic unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success.”

“We believe that Zentiva is a great platform, full of talented people, who we can invest behind to build a new, independent, European generics leader.”

Advent will support the management at Zentiva through investment in operations, production facilities, and the research and development pipeline.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Sanofi CEO Olivier Brandicourt said: “Zentiva is a robust business with a highly talented workforce and we believe it has demonstrated its potential for growth.

“Following a comprehensive review of strategic options for our generic unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success.”

Subject to the finalisation of definitive agreements and regulatory approvals, the acquisition is expected to be completed by the end of this year.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now